Lung cancer trials in Belgium

In Belgium 127 Also abroad 2747

127 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Hasselt, Namur, Roeselare, Sint-Lambrechts-Woluwe
Age
18 years and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Aalst, Brussels, Hasselt, Leuven, Liège, Mons, Roeselare
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Brasschaat, Charleroi, Hasselt, Mechelen
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Anderlecht, Brasschaat, Charleroi, Genk, Gent, Leuven, Sint-Niklaas
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Antwerp, Brugge, Brussels, Gent, Kortrijk, Leuven, Mechelen, Ottignies-Louvain-la-Neuve, Ronse, Yvoir
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Edegem, Leuven, Roeselare
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Auderghem, Edegem, Leuven, Roeselare
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Brussels, Ghent
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 3Taking people
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Where
Charleroi, Edegem, Gent
Age
18 years and over
People
65 worldwide
Run by
Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00
Phase 1Taking people
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Where
Charleroi
Age
18 years and over
People
130 worldwide
Run by
Sairopa B.V.
See details and how to joinNCT05856981
Phase 1/2Taking people
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Where
Gent, Kortrijk, Leuven, Mechelen, Sint-Lambrechts-Woluwe
Age
18 years and over
People
334 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01
Phase 2Taking people
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Genk, Gent, Leuven, Yvoir
Age
18 years and over
People
480 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00
No phaseTaking people
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Where
Brussels, Edegem, Hasselt, Kortrijk, La Louvière, Liège, Sint-Niklaas
Age
18 years and over
People
380 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07230691
Phase 2Taking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
Anderlecht, Edegem, Hasselt, La Louvière, Leuven, Liège, Roeselare
Age
18 years and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
Phase 2/3Taking people
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Where
Brussels, Edegem
Age
18 years and over
People
750 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00
Phase 2/3Taking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Gent, Hasselt, Leuven, Mons, Roeselare, Sint-Lambrechts-Woluwe, Sint-Niklaas
Age
18 years and over
People
1,580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
Phase 3Taking people
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Where
Charleroi, Gent, Hasselt, La Louvière, Liège, Namur
Age
18 years to 90 years
People
507 worldwide
Run by
ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Edegem, Leuven, Liège
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Edegem, Gent, Hasselt
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Brasschaat, Brussels, Charleroi, Edegem, Gent, Hasselt, La Louvière, Liège, Namur, Sint-Niklaas
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Brussels, Charleroi, Kortrijk, Ottignies-Louvain-la-Neuve
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 3Taking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Anderlecht, Brugge, Hasselt, La Louvière, Liège
Age
18 years and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Brussels, Charleroi, Kortrijk, Ottignies-Louvain-la-Neuve, Sint-Niklaas
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
Phase 1/2Taking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Anderlecht, Hasselt, Leuven
Age
18 years and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
Phase 1/2Taking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Hasselt, Liège, Roeselare, Sint-Niklaas
Age
18 years and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00